To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects

NCT04018313 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: CT-P39
BIOLOGICAL: EU-approved Xolair
BIOLOGICAL: CT-P39
BIOLOGICAL: EU-approved Xolair
BIOLOGICAL: US-licensed Xolair

Sponsor

Celltrion